RECEIVED CENTRAL FAX CENTER

AUG 1 5 2006

Attorney Docket: DX01074B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re application of:

Madaline Chirica, et al.

Application No.: 10/667,289

Filed: September 18, 2003

For: MAMMALIAN RECEPTOR

PROTEINS; RELATED

REAGENTS AND METHODS

I hereby cortify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States

→ USPTO

Examiner: J. Seharaseyon

MELANIE LYONS

Art Unit: 1647

Conf. No.: 8664

envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on 1479 - 15, 2006

Postal Service with sufficient postage as first class mail in an

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement dated May 15, 2006 (the "Restriction Requirement"), Applicant submits the following response. A petition for a two-month extension of time, thereby extending the time to reply from June 15, 2006 to August 15, 2006, accompanies this response.

Applicants respectfully request that the Restriction Requirement be withdrawn, and the application be reconsidered, in light of the Preliminary Amendment filed with the application on September 18, 2003.

Although Applicants believe that the aforementioned Preliminary Amendment will be entered and will obviate the current Restriction Requirement, solely in order to comply with the language of 37 CFR 1.143, Applicants provisionally elect Group I, Claims 1-8 whose claims are drawn to a recombinant peptide and compositions containing them, classified in class 530, subclass 350, for example, as discussed in the Office Action.

→ USPTO

Applicants believe that this paper constitutes a full and complete response to the Restriction Requirement. If the Examiner disagrees, Applicants request that he contact the undersigned at his earliest convenience.

Applicants will address the issue of inventorship for the elected claims and amend inventorship appropriately if the elected restriction is made final.

If the Examiner believes that a telephone conference would aid the prosecution of this case in any way, please call the undersigned.

Applicant believes that no additional fees are due with this communication. Should this not be the case, the Commissioner is hereby authorized to debit any charges or refund any overpayments to DNAX Deposit Account No. 04-1239.

Respectfully submitted,

Date: August 15, 2006

Reg. No. 48,451 Attorney for Applicants

Customer No. 028008 DNAX Research, Inc. 901 California Avenue Palo Alto, CA 94304-1104 Telephone (Switchboard): (650) 496-6400

Telephone No. (Direct): (650) 496-6565

Facsimile No.: (650) 496-1200